In the Spotlight...

Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response

Chudnovskiy et al. identified individual DCs presenting tumor-derived antigens to CD4+ T cells in a mouse melanoma model. Using LIPSTIC, a quantitative, CD40-driven, proximity-based labeling protocol ...

DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma

Neeli et al. showed that an i.m.-electroporated DNA vaccine encoding the plasma cell-unique/ MM-overexpressed orphan G protein-coupled receptor GPRC5D prevented s.c. myeloma growth in a murine MM mode...

Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

Sixteen patients with r/r T-ALL, including previous recipients of anti-CD7 CAR T cell therapy and/or allogeneic stem cell transplant, were treated with allogeneic, CD5-disrupted anti-CD5 CAR-T. The st...

Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment

Guo et al. used machine learning-based self-correlation analysis and multiplex IF staining to compare tumor-free tumor-draining lymph node (TDLN) samples from patients with "cold" versus "hot" triple-...

Previous Digests

A type 2 cytokine fusion with type 1 effects – using IL-4 to enhance antitumor immunity

October 9, 2024

Interleukin 4 (IL-4), a cytokine typically associated with humoral (type 2) immune responses, has recently been shown to promote survival in T and B cells. Studying whether IL-4 could be exploited to enhance cancer immunotherapy, Feng and Bai et...

Unmasking higher immunotherapy efficacy potential with a new IL-2 therapy

October 2, 2024

Attempts to avoid systemic toxicity and Treg activation induced by IL-2-directed therapy has resulted in the development of various engineered immunotherapy products that specifically target IL-2Rβ/γ on CD8+ T cells and NK cells. However, these products have, so far...

A sweet spot in the spleen for immune checkpoint blockade responses

September 25, 2024

Immune checkpoint blockade unleashes powerful antitumor T cell responses, but exactly which T cell states are involved and from which anatomic locations they emerge are not fully understood. Investigating these topics, Morgan, Horton, Bhandarkar, et al. profiled T cells...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.